World
A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer.
Publication and source
PublicationSanalda Haber
SourceTIME
Published
CategoryWorld
Summary from the source publisher’s news feed.